Adaptive control methods for the dose individualisation of anticancer agents

Clinical Pharmacokinetics

Volumn 38, Issue 4, 2000, Pages 315-353

  Rousseau, Annick ^a,b,c   Marquet, Pierre ^a   Debord, Jean ^a   Sabot, Christophe ^a   Lachâtre, Gérard ^a,b  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF LIMOGES   (France)

^c DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; HEXAMETHYLENEBISACETAMIDE; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; NAVELBINE; PACLITAXEL; PIRARUBICIN; PLATINUM DERIVATIVE; SURAMIN; TENIPOSIDE; TOPOTECAN; VINBLASTINE; VINDESINE;

AREA UNDER THE CURVE; BAYES THEOREM; BLOOD SAMPLING; BONE MARROW SUPPRESSION; CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOMYOPATHY; CLINICAL TRIAL; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG MONITORING; DRUG TOXICITY; HUMAN; MAXIMUM PERMISSIBLE DOSE; METHODOLOGY; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHARMACODYNAMICS; POPULATION MODEL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME;

EID: 0034056182     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200038040-00003     Document Type: Review

References (191)

1. 1. Ranson MR, Scarffe JH. Population and Bayesian pharmacokinetics in oncology. Clin Oncol 1994; 6: 254-60
2. 2. Freyer G, Ligneau B, Tranchand D, et al. Pharmacokinetic studies in cancer chemotherapy: usefulness in clinical practice. Cancer Treat Rev 1997; 23: 153-69
3. 3. Masson A, Zamboni WC. Pharmacokinetic optimisation of cancer chemotherapy: effects on outcomes. Clin Pharmacokinet 1997; 32: 324-43
4. 4. Canal P, Chatelut E, Guichard S. Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs 1998; 56: 1019-38
5. 5. Evans WE, Crom WR, Abromowitch M, et al. Clinical pharmacodynamics of high dose methotrexate in acute lymphocytic leukemia. N Engl J Med 1986; 314: 471-7
6. 6. Evans WE, Relling MV. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 1989; 16: 327-36
7. 7. Duffull SB, Robinson BA. Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinel 1997; 33: 161-83
8. 8. Sasaki Y. Pharmacological considerations in high-dose chemotherapy. Cancer Chemother Pharmacol 1997; 40 Suppl.: S115-8
9. 9. Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res 1972; 5: 441-59
10. 10. Sheiner LB, Beal S, Rosenberg B, et al. Forecasting individual pharmacokinetics. Clin Pharmacol Ther 1979; 26: 294-305
11. 11. Vozeh S, Muir KT, Sheiner LB, et al. Predicting individual phenytoin dosage. J Pharmacokinet Biopharm 1981; 9: 131-46
12. 12. Sheiner LB, Beal SL. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci 1982; 71: 1344-8
13. 13. Aarons L. Population pharmacokinetics. Int J Clin Pharmacol Ther Toxicol 1992; 30: 520-2
14. 14. Sheiner LB, Ludden TM. Population pharmacokinetics/dynamics. Annu Rev Pharmacol Toxicol 1992; 32: 185-209
15. 15. Vozeh S, Steimer JL, Rowland M, et al. The use of population pharmacokinetics in drug development. Clin Pharmacokinet 1996; 30: 81-93
16. 16. Thomson AH, Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet 1992; 22: 447-67
17. 17. Jelliffe RW, Schumitzky A, Bayard D, et al. Model-based, goal-oriented individualised drug therapy. Clin Pharmacokinet 1998; 34: 57-77
18. 18. Aarons L. Population pharmacokinetics: theory and practice. Br J Clin Pharmacol 1991; 32: 669-70
19. 19. Mandema JW. Population pharmacokinetics/pharmacodynamics of analgesics: theory and applications. In: Proceedings of Cost B1 medicine. Brussels: European Commission; 1997 Feb 12-14; Geneva, 74-82
20. 20. Beal S, Sheiner L. NONMEM user's guide. I: users basic guide. San Francisco: Division of Clinical Pharmacology, University of California, 1979
21. 21. Sheiner LB. Analysis of pharmacokinetic data using parametric models. I: regression models. J Pharmacokinet Biopharm 1984; 12: 93-118
22. 22. Sheiner LB. Analysis of pharmacokinetic data using parametric models. II: point estimates of an individual's parameters. J Pharmacokinet Biopharm 1985; 13: 515-40
23. 23. Sheiner LB. Analysis of pharmacokinetic data using parametric models. III: hypothesis tests and confidence intervals. J Pharmacokinet Biopharm 1986; 14: 539-56
24. 24. Aarons L. Software for population pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1999; 36: 255-64
25. 25. Mallet A. A maximum likelihood estimation method for random coefficient regression. Biometrika 1986; 73: 645-56
26. 26. Schumitzky A. Nonparametric EM algorithms for estimating prior distributions. App Math Comput 1991; 45: 141-57
27. 27. Bruno R, Vivier N, Vergniol JC, et al. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 1996; 24: 153-72
28. 28. Samara E, Granneman R. Role of population pharmacokinetics in drug development: a pharmaceutical industry perspective. Clin Pharmacokinet 1997; 32: 294-312
29. 29. Sun H, Fadiran EO, Jones CD, et al. Population pharmacokinetics: a regulatory perspective. Clin Pharmacokinet 1999; 37: 41-58
30. 30. Radamski KM, Davis GA, Chandler MHH. General versus subpopulation values in Bayesian prediction of aminoglycoside pharmacokinetics in hematology-oncology patients. Am J Health Syst Pharm 1997; 54: 541-4
31. 31. Abrahms K, Ashby D, Errington D. Simple Bayesian analysis in clinical trials: a tutorial. Control Clin Trials 1994; 15: 349-59
32. 32. Jelliffe RW, Schumitzky A, Guilder MV, et al. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptative control. Ther Drug Monit 1993; 15: 380-93
33. 33. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-12
34. 34. Ensom MH, Davis GA, Cropp CD, et al. Clinical pharmacokinetics in the 21st century. Clin Pharmacokinet 1998; 34: 265-79
35. 35. Evans WE, Relling MV, Rodman JH, et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998; 338; 499-505
36. 36. Fety R, Rolland F, Barberi-Heyob M, et al. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res 1998; 4: 2039-45
37. 37. Karlsson MO, Molnar V, Bergh J, et al. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationships exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther 1998; 63: 11-25
38. 38. Minami H, Sasaki Y, Saijo N, et al. Indirect-response model for the time course of leukopenia with anticancer drugs. Clin Pharmacol Ther 1998; 64: 511-21
39. 39. Goldie JH, Price LA, Harrap KR. Methotrexate toxicity: correlation with duration of administration, plasma levels, dose and excretion pattern. Eur J Cancer 1972; 8: 409-14
40. 40. Stoller RG, Jacobs SA, Drake JC, et al. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 1977; 297: 630-4
41. 41. Evans WE, Pratt CB, Taylor RH, et al. Pharmacokinetic monitoring of high-dose methotrexate: early recognition of high-risks patients. Cancer Chemother Pharmacol 1979; 3: 161-6
42. 42. Graf N, Winkler K, Betlemovic M, et al. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 1994; 12: 1443-51
43. 43. Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian study. J Clin Oncol 1984; 2: 617-24
44. 44. Delepine N, Desbois JC, Delepine G, et al. Individualisation de posologie de methotrexate haut dose par le dosage des concentrations plasmatiques, intérêt thérapeutique dans le sarcome osteogenique. Bull Cancer 1989; 76: 913-19
45. 45. Monjanel S, Rigault JP, Cano JP, et al. High-dose methotrexate: preliminary evaluation of pharmacokinetic approach. Cancer Chemother Pharm 1979; 3: 189-96
46. 46. Cano JP, Bruno R, Lena N, et al. Dosage predictions in high-dose methotrexate infusions: Pt I. Evaluation of the classic test dose protocol. Cancer Drug Deliv 1985; 2: 271-6
47. 47. Iliadis A, Bachir-Raho M, Bruno R, et al. Bayesian estimation and prediction of clearance in high-dose methotrexate infusions. J Pharmacokinet Biopharm 1985; 13: 101-15
48. 48. Favre R, Charbit M, Rinaldi Y, et al. La pharmacocinétique dans les études de phase IV pour la prévision du schéma thérapeutique. Bull Cancer 1988; 75: 541-50
49. 49. Bruno R, Iliadis A, Favre R, et al. Dosage predictions in high-dose methotrexate infusions: Pt 2. Bayesian estimation of methotrexate clearance. Cancer Drug Deliv 1985; 2: 277-83
50. 50. Sabot C, Debord J, Roullet B, et al. Bayesian estimation and population pharmacokinetic parameters of high dose methotrexate in osteosarcoma. Clin Res Reg Affairs 1993; 10: 233-41
51. 51. Pignon T, Lacarelle B, Duffaud F, et al. Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. Cancer Chemother Pharmacol 1994; 33: 420-4
52. 52. Pignon T, Lacarelle B, Duffaud F, et al. Dosage adjustment of high-dose methotrexate using Bayesian estimation: a comparative study of two different concentrations at the end of 8-h infusions. Ther Drug Monit 1995; 17: 471-8
53. 53. Sabot C, Debord J, Roullet B, et al. Comparison of 2-and 3-compartment models for the Bayesian estimation of methotrexate pharmacokinetics. Int J Clin Pharmacol Ther 1995; 33: 164-9
54. 54. Sabot C, Debord J, Marquet P, et al. High dose methotrexate adaptation in cancer adults and children using Bayesian estimation. Update on bone and soft tissue tumors - an International Conference; 1997 Apr 2; Paris
55. 55. Bressolle F, Costa P, Rouzier-Panis R, et al. A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modelling program P-PHARM. Eur J Clin Pharmacol 1996; 49: 285-92
56. 56. Bressolle F, Bologna C, Kinowski JM, et al. Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. Ann Rheum Dis 1998; 57: 110-3
57. 57. Debord J, Carpentier N, Sabot C, et al. Influence of biological variables upon pharmacokinetic parameters of intramuscular methotrexate in rheumatoid arthritis. Int J Clin Pharmacol Ther 1998; 36: 227-30
58. 58. Carpentier N, Bertin P, Marquet P, et al. Is there an optimal time to administer methotrexate in the treatment of rheumatoid arthritis? J Rheumatol 1998; 25: 1270-5
59. 59. Crom WR, Glynn-Barnhart AM, Rodman JH, et al. Pharmacokinetics of anticancer drugs in children. Clin Pharmacokinet 1987; 12: 168-213
60. 60. Rodman JH, Abromowitch M, Sinkule JA, et al. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial. J Clin Oncol 1987; 5: 1007-14
61. 61. Rodman JH, Furman WL, Sunderland M, et al. Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients. J Clin Oncol 1993; 11: 287-93
62. 62. Rodman JH, Sunderland M, Kavanagh RL, et al. Pharmacokinetics of continuous infusion of methotrexate and teniposide in pediatric cancer patients. Cancer Res 1990; 15; 50: 4267-71
63. 63. Evene E, Chatelut E, Tranchand B, et al. Bayesian estimation of pharmacokinetic parameters of etoposide. Bull Cancer 1997; 84: 699-703
64. 64. Tranchand B, Amsellen C, Chatelut E, et al. A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 1999; 43: 316-22
65. 65. Launay MC, Milano G, Iliadis A, et al. A limited sampling procedure for estimating adriamycin pharmacokinetics in cancer patients. Br J Cancer 1989; 60: 89-92
66. 66. Bressolle F, Ray P, Jacquet JM, et al. Bayesian estimation of doxorubicin pharmacokinetic parameters. Cancer Chemother Pharmacol 1991; 29: 53-60
67. 67. Marchiset-Leca, Feca FR, Galeani A, et al. A limited sampling strategy for the study of pirarubicin pharmacokinetics in humans. Cancer Chemother Pharmacol 1995; 36: 233-8
68. 68. Karato A, Sassaki Y, Shinkai T, et al. Phase I study of CPT-11 and etoposide in patients with refractory solid tumors. J Clin Oncol 1993; 11: 2030-5
69. 69. Yamamoto N, Tamura T, Karato A, et al. CPT-11: population pharmacokinetic model and estimation of pharmacokinetics using the Bayesian method in patients with lung cancer. Jpn J Cancer Res 1994; 85: 972-7
70. 70. Nakashima H, Lieberman R, Karato A, et al. Efficient sampling strategies for forecasting pharmacokinetic parameters of irinotecan (CPT-11): implication for area under the concentration-time curve monitoring. Ther Drug Monit 1995; 17: 221-9
71. 71. Stewart CF, Baker SD, Heideman RL, et al. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J Clin Oncol 1994; 12: 1946-54
72. 72. Furman WL, Baker SD, Pratt CB, et al. Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. J Clin Oncol 1996; 14: 1504-11
73. 73. Sabot C, Marquet P, Debord J, et al. Bayesian pharmacokinetic estimation of vinorelbine in non-small-cell lung cancer patients. Eur J Clin Pharmacol 1998; 54: 171-5
74. 74. Conley BA, Forrest A, Merrill JE, et al. Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580). Cancer Res 1989; 49: 3436-40
75. 75. Dawson NA, Figg WD, Cooper MR, et al. Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. J Clin Oncol 1997; 15: 1470-7
76. 76. Baille P, Bruno R, Schellens JHM, et al. Optimal sampling strategies for Bayesian estimation of docetaxel (taxotere) clearance. Clin Cancer Res 1997; 3: 1535-8
77. 77. Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16: 187-96
78. 78. Budman DR, Igwemezie LN, Kaul S, et al. Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3 and 5 in patients with solid tumors. J Clin Oncol 1994; 12: 1902-9
79. 79. Relling M, McLeod H, Bowman L, et al. Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin. Clin Pharmacol Ther 1994; 56: 503-11
80. 80. Rodman JH, Murry DJ, Madden T, et al. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. J Clin Oncol 1994; 12: 2390-7
81. 81. Ratain MJ, Schilsky RL, Choi KE, et al. Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther 1989; 45: 226-33
82. 82. Mick R, Ratain MJ. Modeling interpatient pharmacodynamic variability of etoposide. J Natl Cancer Inst 1991; 83: 1560-4
83. 83. Joel SP, Shah R, Slevin ML. Etoposide dosage and pharmacodynamics. Cancer Chemother Pharmacol 1994; 34 Suppl.: S69-75
84. 84. Miller AA, Stewart CF, Tolley EA. Clinical pharmacodynamics of continuous-infusion etoposide. Cancer Chemother Pharmacol 1990; 25: 361-6
85. 85. Miller AA, Tolley EA, Niell HB, et al. Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer. Cancer Chemother Pharmacol 1992; 31: 161-6
86. 86. Minami H, Shimokata K, Saka H, et al. Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer. J Clin Oncol 1993; 11: 1602-8
87. 87. Desoize B, Marechal F, Cattan A. Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours. Br J Cancer 1990; 62: 840-1
88. 88. Nguyen L, Chatelut E, Chevreau C, et al. Population pharmacokinetics of total and unbound etoposide. Cancer Chemother Pharmacol 1998; 41: 125-32
89. 89. Clark PI, Slevein ML, Joel SP, et al. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 1994; 12: 1427-35
90. 90. Stewart CF, Arbuck SG, Fleming RA, et al. Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clin Pharmacol Ther 1991; 50: 385-93
91. 91. Bonfante V, Bonadonna G, Villani F, et al. Preliminary phase I study of 4′-epi-adriamycin. Cancer Treat Rep 1979; 63: 915-8
92. 92. Ackland SP, Ratain MJ, Vozelzang NJ, et al. Pharmacokinetics and pharmacodynamics of long term continuous infusion doxorubicin. Clin Pharmacol Ther 1989; 45: 340-7
93. 93. Eichholtz-Wirth H. Dependence of the cytostatic effect of adryamycin on drug concentration and exposure time in vitro. Br J Cancer 1980; 41: 886-91
94. 94. Ritch P, Occhipintin SJ, Skramstad KS, et al. Increased relative effectiveness of doxorubicin against slowly proliferating sarcoma 180 cells after prolonged drug exposure. Cancer Treat Rep 1982; 66: 1159-68
95. 95. Jacquet JM, Bressolle F, Galtier M. Doxorubicin and doxorubicinol: intra-and inter-individual variations of pharmacokinetic parameters. Cancer Chemother Pharmacol 1990; 27: 219-25
96. 96. Gurney HP, Ackland S, Gebski V, et al. Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. J Clin Oncol 1998; 16: 2299-304
97. 97. Robert J, David M, Huet S, et al. Pharmacokinetics and metabolism of pirarubicin in advanced cancer patients. Eur J Cancer Clin Oncol 1988; 24: 1289-94
98. 98. Robert J, Monnier A, Poutignat N, et al. A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients. Cancer Chemother Pharmacol 1991; 29: 75-9
99. 99. Jacquet JM, Galtier M, Bressolle F, et al. A sensitive and reproducible HPLC assay for doxorubicin and pirarubicin. J Pharmaceut Biomed 1992; 10: 343-8
100. 100. Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 1997; 33: 245-59
101. 101. Mick R, Gupta E, Vokes VV, et al. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. J Clin Oncol 1996; 14: 2012-9
102. 102. Kanzawa F, Sugimoto Y, Minato K, et al. Establishment of a campthotecin analogue (CPT-11)-resistant cell line of human small cell lung cancer: characterization and mechanism of resistance. Cancer Res 1990; 50: 5019-24
103. 103. Ohe Y, Saski Y, Shinkai T, et al. Phase I study and pharmacokinetics of CPT-II with 5-day continuous infusion. J Natl Cancer Inst 1992; 64: 972-4
104. 104. Rowinsky EK, Grochow LB, Ettinger DS, et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 1994; 54: 427-36
105. 105. Gupta E, Lestingi TM, Mick R, et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994; 54: 3723-5
106. 106. Kantarjian HM, Beran M, Ellis A, et al. Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 1993; 81: 1146-51
107. 107. Verweij J, Lund B, Beijnen J, et al. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 1993; 4: 673-8
108. 108. Hochster H, Liebes L, Speyer J, et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 1994; 12: 553-9
109. 109. Swisher EM, Mutch DG, Rader JS, et al. Topotecan in platinum-and paclitaxel-resistant ovarian cancer. Gynecol Oncol 1997; 66: 480-6
110. 110. Brogden RN, Wiseman LR. Topotecan: a review of its potential in advanced ovarian cancer. Drugs 1998; 56: 709-23
111. 111. Haas NB, LaCreta FP, Walczak J, et al. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res 1994 Mar 1; 54 (5): 1220-6
112. 112. Herben V, ten Bokkel Huinink W, Beijnen JH. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 1996; 31: 85-102
113. 113. Gregg RW, Molepo JM, Monpetit VJ, et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992; 10: 795-803
114. 114. Kawa K, Ohnuma N, Kaneko M, et al. Long term survivors of advanced neuroblastoma with MYCN amplification: a report of 19 patients surviving disease-free for more than 66 months. J Clin Oncol 1999; 17: 3216-20
115. 115. Dechamp C, Rinaldi Y, Durand A, et al. Etude pharmacocinétique du platine ultrafiltrable 'actif au cours de perfusions continues à débit constant sur 5 jours de cisplatine avec adaptation de posologie. Bull Cancer 1989; 76: 883-5
116. 116. Calvert AH, Newell, Gumbrell LA. Carrboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 11: 1748-56
117. 117. Guillet P, Monjanel S, Nicoara A, et al. A Bayesian dosing method for carboplatin given by continuous infusion for 120h. Cancer Chemother Pharmacol 1997; 40: 143-9
118. 118. Egorin MJ, Van Echo DD, Olman EA. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutane-dicarboxylatoplatinum. Cancer Res 1985; 45: 6502-6
119. 119. Newell DR, Siddik ZH, Gumbrell LA, et al. Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin. Eur J Cancer Clin Oncol 1987; 23: 1399-405
120. 120. Newell DR, Pearson A, Balmanno K, et al. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. J Clin Oncol 1993; 12: 2314-23
121. 121. Reyno LM, Egorin MJ, Canetta RM, et al. Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. J Clin Oncol 1993; 11: 1156-64
122. 122. Horwich A, Dearnaley DP, Nicholls J, et al. Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors. J Clin Oncol 1991; 9: 62-9
123. 123. Jodrell DI, Egorin MJ, Canetta RM, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992; 10: 520-8
124. 124. Boddy AV, Calvert AH. Individualized dosing of anticancer drugs. In: Schildsky RL, Milano GA, Ratain MJ, editors. Principles of antincoplastic drug development and pharmacology. New York: M Dekker Inc., 1996: 435-55
125. 125. Calvert AH, Lind MJ, Ghazal-Aswad S, et al. Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial cancer: a phase I dose-intensity escalation study. Semin Oncol 1994; 21: 1-6
126. 126. Lind MJ, Ghazal-Aswad S, Gumbrell L. Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancer. J Clin Oncol 1996; 14: 800-5
127. 127. Murry DJ, Sandlund JT, Stricklin LM, et al. Pharmacokinetics and acute renal effects of continuously infused carboplatin. Clin Pharmacol Ther 1993; 54: 374-80
128. 128. Calvert AH, Harland SJ, Newell DR, et al. Early clinical studies with cis-diammine-1, 1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 1982; 9: 140-7
129. 129. Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995; 87: 573-80
130. 130. Desoize B, Dumont P, Manot L, et al. Evaluation prospective d'une méthode d'adaptation de posologie du cisplatine [abstract]. Bull Cancer 1995; 82: 411
131. 131. Peng B, Boddy AV, Cole M, et al. Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients. Eur J Cancer 1995; 31: 1804-10
132. 132. Desoize B, Dufour R, Urien S. et al. Evaluation of two dose individualisation methods for carboplatin. Anticancer Res 1996; 16: 2073-8
133. 133. Duffull SB, Begg EJ, Robinson BA, et al. A sequential Bayesian algorithm for dose individualisation of carboplatin. Cancer Chemother Pharmacol 1997; 39 (4): 317-26
134. 134. Johansen MJ, Madden T, Mehra RC, et al. Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer. J Clin Oncol 1997; 15: 1481-91
135. 135. Doz F, Urien S, Chatelut E, et al. A limited-sampling method for evaluation of the area under the curve of ultrafilterable carboplatin in children. Cancer Chemother Pharmacol 1998; 42: 250-4
136. 136. Chatelut E, Pivot X, Otto J, et al. A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage. Eur J Cancer 2000; 36: 264-9
137. 137. Stein CA, LaRocca RV, Thomas R, et al. Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 1989; 7: 499-505
138. 138. LaRocca RV, Cooper MR, Uhrich M, et al. Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation. Urol Clin North Am 1991; 18: 123-9
139. 139. Scher HI, Jodrell DI, Iversen JM, et al. Use of adaptive control with feedback to individualize suramin dosing. Cancer Res 1992; 52: 64-70
140. 140. Eisenberger MA, Sinibaldi VJ, Reyno LM, et al. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J Clin Oncol 1995; 13: 2174-86
141. 141. Cooper MR, Lieberman R, La Rocca RV, et al. Adaptive control with feedback strategies for suramin dosing. Clin Pharmacol Ther 1992; 52: 11-23
142. 142. Collins JM, Klecker RW, Yarchoan R, et al. Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol 1986; 26: 22-6
143. 143. Eisenberger MA, Reyno LM, Jodrell DI, et al. Suramin, an active drug for prostate cancer: interim observations in a phase I trial. J Natl Cancer Inst 1993; 85: 611-21
144. 144. Jodrell DI, Reyno LM, Sridhara R, et al. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer. J Clin Oncol 1994; 12: 166-75
145. 145. Falcone A, Pfanner E, Cianci C, et al. Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy: a phase II study. Cancer 1995; 75: 440-3
146. 146. Rosen PJ, Mendoza EF, Landaw EM, et al. Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy. J Clin Oncol 1996; 14: 1626-36
147. 147. Motzer RJ, Nanus DM, O'Moore P, et al. Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics and tumor growth factor expression. Cancer Res 1992; 52: 5775-9
148. 148. Crawford J, O'Rourke M, Schiller JH, et al. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J Clin Oncol 1996; 14: 2774-84
149. 149. Robieux I, Sorio R, Borsatti E, et al. Pharmacokinetics of vinorelbine in patients with liver metastases. Clin Pharmacol Ther 1996; 59: 32-40
150. 150. Levêque D, Jehl F. Clinical pharmacokinetics of vinorelbine. Clin Pharmacokinet 1996; 31: 184-97
151. 151. Fibach E, Reuben RC, Rifkind RA, et al. Effect of hexamethylene bisacetamide on the commitment to differentiation of murine erythroleukemia cells. Cancer Res 1977; 37: 440-4
152. 152. Marks PA, Sheffery M, Rifkind RA. Induction of transformed cells to terminal differentiation and the modulation of gene expression. Cancer Res 1987; 47: 659-66
153. 153. Bruno R, Sanderink GJ. Pharmacokinetics and metabolism of taxotere (docetaxel). Cancer Surv 1993; 17: 305-13
154. 154. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995; 13: 2643-55
155. 155. Gamelin E, Boisdron-Celle M. Dose monitoring of S-fluorouracil in patients with colorectal or head and neck cancer - status of the art. Crit Rev Oncol Hematol 1999; 30: 71-9
156. 156. Young AM, Daryanani S, Kerr DJ. Can pharmacokinetic monitoring improve clinical use of fluorouracil. Clin Pharmacokinet 1999; 36: 391-8
157. 157. Milano G, Etienne MC, Renée N, et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 1994; 12: 1291-5
158. 158. Gamelin E, Boisdron-Celle M, Delva R, et al. Long term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 1998; 16: 1470-8
159. 159. Santini J, Milano G, Thyss A, et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 1989; 59: 287-90
160. 160. Bressolle F, Joulia JM, Pinguet F, et al. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol 1999; 44: 295-302
161. 161. Evans WE, Rodman JH, Relling MV, et al. Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia. Semin Hematol 1991; 28: 15-21
162. 162. Bellissant E, Sébille V, Paintaud G. Methodological issues in pharmacokinetic-pharmacodynamic modelling. Clin Pharmacokinet 1998; 35: 151-66
163. 163. Evans WE. Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose-intensity. Blut 1988; 56: 241-8
164. 164. Evans WE, Rodman JH, Relling MV, et al. Concept of maximum tolerated systemic exposure and its application to phase I-II studies of anticancer drugs. Med Pediatr Oncol 1991; 19: 153-9
165. 165. Evans WE. Alternative approaches for phase I studies of anticancer drugs: a role for therapeutic drug monitoring. Ther Drug Monit 1993; 15: 492-7
166. 166. Fernandez de Gatta MM, Garcia MJ, Lanao JM, et al. Bayesian forecasting in paediatric populations. Clin Pharmacokinet 1996; 31: 325-30
167. 167. D'Argenio DZ. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 1981; 9 (6): 739-56
168. 168. Paintaud G, Alvan G, Berninger E, et al. The concentration-effect relationship of quinine-induced hearing impairment. Clin Pharmacol Ther 1994; 55: 317-23
169. 169. Ludden TM, Beal SL, Sheiner LB. Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection. J Pharmacokinet Biopharm 1994; 22: 431-45
170. 170. Vozeh S. Applications of population approach to clinical pharmacokinetics and validation of the results. In: Rowland M, Aarons L, editors. New strategies in drug development and clinical evaluation: the population approach. Luxembourg: Commission of the European Communities, 1992: 107-20
171. 171. Bowers LD. Analytical goals in therapeutic drug monitoring. Clin Chem 1998; 44: 375-80
172. 172. Stockl D, Dewitte K, Thienpont LM. Validity of linear regression in method comparison studies: is it limited by the statistical model or the quality of the analytical input data? Clin Chem 1998; 44: 2340-6
173. 173. Petersen PH, Stockl D, Blaabjerg O, et al. Graphical interpretation of analytical data from comparison of a field method with reference method by use of difference plots. Clin Chem 1997; 43: 2039-46
174. 174. Stromgren AS, Sorensen BT, Jakobsen P, et al. A limited sampling method for estimation of the etoposide area under the curve. Cancer Chemother Pharmacol 1993; 32: 226-30
175. 175. Ratain MJ, Robert J, van der Vijgh WJ, et al. Limited sampling models for doxorubicin pharmacokinetics. J Clin Oncol 1991; 9: 871-6
176. 176. Sorensen BT, Stromgren A, Jakobsen P, et al. A limited sampling method for estimation of the carboplatin area under the curve. Cancer Chemother Pharmacol 1993; 31: 324-7
177. 177. Miyazaki M, Fujiwara Y, Takahashi T, et al. Limited-sampling models for estimation of the carboplatin area under the curve. Anticancer Res 1997; 17: 4571-5
178. 178. Egorin MJ, Forrest A, Belani CP, et al. A limited sampling strategy for cyclophosphamide pharmacokinetics. Cancer Res 1989; 49: 3129-33
179. 179. Moore MJ, Bunting P, Yuan S. Development and validation of a limited sampling strategy for 5-fluorouracil given by bolus intravenous administration. Ther Drug Monit 1993; 15; 394-9
180. 180. Ratain MJ, Schilsky RLR, Conley BA, et al. Pharmacodynamics in cancer therapy. J Clin Oncol 1990; 8: 1739-53
181. 181. Chabner BA, Allegra CJ, Curt GA, et al. Polyglutamation of methotrexate: is methotrexate a prodrug? J Clin Invest 1985; 76: 907-12
182. 182. Stewart CF, Fleming RA, Arbuck SG, et al. Prospective evaluation of a model for predicting etoposide plasma protein binding in cancer patients. Cancer Res 1990; 50: 6854-6
183. 183. Evans WE, Rodman JH, Relling MV, et al. Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemia. J Pharmacol Exp Ther 1992; 260: 71-7
184. 184. Joel SP, Shah R, Clark PE, et al. Predicting etoposide toxicity: relationship to organ function and protein binding. J Clin Oncol 1996; 14: 257-67
185. 185. Marquet P, Lachatre G. Liquid chromatography-mass spectrometry: potential in forensic and clinical toxicology. J Chromatogr B 1999; 733: 93-118
186. 186. Hon YY, Evans WE. Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. Clin Chem 1998; 44: 388-400
187. 187. Maxwell R. New techniques in the pharmacokinetic analysis of cancer drugs: III. Nuclear magnetic resonance. Cancer Surv 1993; 17: 415-23
188. 188. Levy G. Predicting effective drug concentrations for individual patients: determinants of pharmacodynamic variability. Clin Pharmacokinet 1998; 34: 323-33
189. 189. Bruguerolle B. Chronopharmacokinetics: current status. Clin Pharmacokinet 1998; 35: 83-94
190. 190. Sandstrom M, Freijs A, Larsson R, et al. Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. J Clin Oncol 1996; 14: 1581-8
191. 191. Yates CR, Pui CH, Evans WE. Pharmacodynamic monitoring of cancer chemotherapy: childhood acute lymphoblastic as a model. Ther Drug Monit 1998; 20: 453-8